Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EPS (Basic) (2023 - 2025)

Historic EPS (Basic) for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$2.28.

  • Inhibrx Biosciences' EPS (Basic) rose 1971.83% to -$2.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.96, marking a year-over-year decrease of 11075.54%. This contributed to the annual value of $114.01 for FY2024, which is 65668.81% up from last year.
  • Per Inhibrx Biosciences' latest filing, its EPS (Basic) stood at -$2.28 for Q3 2025, which was up 1971.83% from -$1.85 recorded in Q2 2025.
  • Inhibrx Biosciences' EPS (Basic)'s 5-year high stood at $127.1 during Q2 2024, with a 5-year trough of -$7.29 in Q4 2023.
  • Its 3-year average for EPS (Basic) is $9.23, with a median of -$3.04 in 2024.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 304895.59% in 2024, then crashed by 10145.55% in 2025.
  • Inhibrx Biosciences' EPS (Basic) (Quarter) stood at -$7.29 in 2023, then skyrocketed by 55.64% to -$3.23 in 2024, then increased by 29.49% to -$2.28 in 2025.
  • Its last three reported values are -$2.28 in Q3 2025, -$1.85 for Q2 2025, and -$2.8 during Q1 2025.